We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+42.67%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.86B
AUM Growth
+$458M
Cap. Flow
+$125M
Cap. Flow %
6.71%
Top 10 Hldgs %
60.44%
Holding
79
New
30
Increased
3
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
SPRY icon
ARS Pharmaceuticals
SPRY
+$84.6M
2
STTK icon
Shattuck Labs
STTK
+$79M
3
SLDB icon
Solid Biosciences
SLDB
+$33.6M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$18.9M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.9M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$99.6M
2
STRO icon
Sutro Biopharma
STRO
+$50M
3
SURF
Surface Oncology, Inc. Common Stock
SURF
+$28.5M
4
ASMB icon
Assembly Biosciences
ASMB
+$24.9M
5
CBIO
Crescent Biopharma
CBIO
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.73%
2 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
26
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$10.8M 0.58%
+100,000
New +$9.13M
VINC
27
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$10M 0.54%
24,025
-7,500
-24% -$2.36M
ACRS icon
28
Aclaris Therapeutics
ACRS
$744M
$9.77M 0.53%
1,509,812
-21,500
-1% -$90.7K
ALPN
29
DELISTED
Alpine Immune Sciences Inc
ALPN
$9.34M 0.5%
741,290
– –
TNGX icon
30
Tango Therapeutics
TNGX
$4.34B
$9.15M 0.49%
800,000
– –
ITOS
31
DELISTED
iTeos Therapeutics
ITOS
$8.79M 0.47%
260,000
– –
CMAX
32
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$7.51M 0.4%
+16,053
New +$5.39M
CERE
33
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$6.63M 0.36%
+400,000
New +$5.2M
CCCC icon
34
C4 Therapeutics
CCCC
$393M
$6.63M 0.36%
+200,000
New +$5.8M
KYMR icon
35
Kymera Therapeutics
KYMR
$8.73B
$6.2M 0.33%
100,000
– –
LOGC
36
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$5.91M 0.32%
+775,000
New +$5.18M
JYAC
37
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$5.15M 0.28%
+500,000
New +$5.09M
OBIO icon
38
Orchestra BioMed
OBIO
$231M
$5.12M 0.28%
400,000
– –
PANA.U
39
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$4.98M 0.27%
390,000
– –
CYCN icon
40
Cyclerion Therapeutics
CYCN
$15.2M
$4.92M 0.26%
80,314
-56,800
-41% -$3.87M
LKFT
41
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
$4.62M 0.25%
+46,666
New +$5.71M
DYN icon
42
Dyne Therapeutics
DYN
$4.28B
$4.51M 0.24%
215,000
– –
NGM
43
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$4.35M 0.23%
+143,567
New +$3.14M
CDAK
44
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$3.72M 0.2%
+115,195
New +$1.52M
VINCW
45
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
$3.14M 0.17%
+150,000
New +$499K
PMVP icon
46
PMV Pharmaceuticals
PMVP
$58.7M
$3.08M 0.17%
50,000
– –
GOSS icon
47
Gossamer Bio
GOSS
$100M
$2.85M 0.15%
+294,221
New +$2.9M
MTCR
48
DELISTED
Metacrine, Inc. Common Stock
MTCR
$2.62M 0.14%
333,332
– –
MLTX icon
49
MoonLake Immunotherapeutics
MLTX
$1.59B
$2.27M 0.12%
+200,000
New +$2.12M
BLSA
50
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.23M 0.12%
+200,000
New +$2.14M
1
2
3 4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2020 Portfolio in Review

As of Q4 2020, EcoR1 Capital held 79 positions worth $1.86B, up 33% from $1.4B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

EcoR1 Capital deployed $125M of net new capital in Q4 2020, opening 30 new positions and adding to 3 existing holdings. Its largest new stake was ARS Pharmaceuticals: 2,533,635 shares worth $117M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Kura Oncology, an estimated $99.6M trimmed.

  • EcoR1 Capital's largest Q4 2020 buy was ARS Pharmaceuticals: 2,533,635 shares worth $117M.
  • EcoR1 Capital added most to Oric Pharmaceuticals in Q4 2020, an estimated $12.9M increase.
  • EcoR1 Capital's biggest Q4 2020 reduction was Kura Oncology, cutting an estimated $99.6M.
  • EcoR1 Capital fully exited Assembly Biosciences in Q4 2020, selling an estimated $24.9M.
  • EcoR1 Capital's ten largest holdings make up 60% of its $1.86B portfolio in Q4 2020.
  • EcoR1 Capital opened 30 new positions and closed 14 in Q4 2020.
  • EcoR1 Capital's portfolio value rose 33% quarter-over-quarter to $1.86B.

Based on EcoR1 Capital's 13F filing for Q4 2020, filed 16 Feb 2021.